A Polymorphism in MAPKAPK3 Affects Response to Interferon Therapy for Chronic Hepatitis C

Abstract

The SNP rs3792323 in MAPKAPK3 associates with the outcome of IFN therapy in patients with HCV genotype 1b. Our functional analyses indicate that MAPKAPK3 inhibits IFN-alfa-induced antiviral activity.

Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients

“…We recently reported that a SNP in the MAPKAPK3 gene is associated with response to interferon therapy [14]. More recently, three groups of researchers found that several SNPs in the IL28 locus are related to the effectiveness of combination therapy [15][16][17].…”

Genes Determining the Course of Virus Persistence in the Liver: Lessons from Murine Infection with Lymphocytic Choriomeningitis Virus

“…In humans, a polymorphism of STAT1 has been found to be associated with chronic HCV infection; this finding suggests that signalling by IFN-I, IFN-γ (type II), or both is essential for control of the virus [84]. In humans, a polymorphism in the IFN receptor can influence the outcome of IFN therapy [28,29]. Researchers recently described a STAT1 gene mutation that leads to an almost complete absence of IFN signalling.…”

Genética y tratamiento de la hepatitis C: ¿hacia un tratamiento personalizado?

“…Existen datos sobre un posible efecto de los genes que codifican el receptor de interferón tipo 1 (IFNAR1) y a la proteincinasa 3 (MAPKAPK3) sobre la respuesta al tratamiento 4,5 . Asimismo se conoce que existen diferencias en la respuesta al tratamiento relacionadas con la etnia de los pacientes, siendo los porcentajes de respuesta en los afroamericanos significativamente menor que en aquellos de origen caucásico o asiáticos.…”